Page 42 - Read Online
P. 42
Briggs et al. J Cancer Metastasis Treat 2021;7:46 https://dx.doi.org/10.20517/2394-4722.2021.84 Page 11 of 13
Contributed to methodology, data curation, writing - original draft: Briggs LG
Availability of data and materials
Not applicable.
Financial support and sponsorship
None.
Conflicts of interest
Lee RJ: Astellas, Bayer, Dendreon, Exelixis, GE Heathcare, Janssen (advisory board); Janssen (research
funding).
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Copyright
© The Author(s) 2021.
REFERENCES
1. Strimbu K, Tavel JA. What are Biomarkers. Curr Opin HIV AIDS 2010;5:463-6. DOI PubMed PMC
2. Mickley A, Kovaleva O, Kzhyshkowska J, Gratchev A. Molecular and immunologic markers of kidney cancer-potential applications in
predictive, preventive and personalized medicine. EPMA J 2015;6:20. DOI PubMed PMC
3. Graham J, Dudani S, Heng DYC. Prognostication in kidney cancer: recent advances and future directions. J Clin Oncol
2018:JCO2018790147. DOI PubMed
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. DOI PubMed
5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI PubMed
6. Cohen HT, Mcgovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90. DOI PubMed
7. Cancer Stat Facts: kidney and renal pelvis cancer. Surveillance, Epidemiology, and End Results Program. Available from:
https://seer.cancer.gov/statfacts/html/kidrp.html. [Last accessed on 1 Jul 2021].
8. Brown LC, Desai K, Zhang T, Ornstein MC. The immunotherapy landscape in renal cell carcinoma. BioDrugs 2020;34:733-48. DOI
PubMed
9. Carretero-González A, Lora D, Martín Sobrino I, et al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell
carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel) 2020;12:1945. DOI PubMed PMC
10. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies
against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96. DOI PubMed
11. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model
for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41. DOI PubMed
12. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with
vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9. DOI
PubMed
13. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell
Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14:141-8. DOI PubMed PMC
14. Négrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal
carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002;13:1460-8. DOI PubMed
15. Manola J, Royston P, Elson P, et al; International Kidney Cancer Working Group. Prognostic model for survival in patients with
metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 2011;17:5443-50. DOI
PubMed PMC
16. Peña C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma:
results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010;16:4853-63.
DOI PubMed
17. Marta GN, Velho PI, Bonadio RRC, et al. Prognostic value of systemic inflammatory biomarkers in patients with metastatic renal cell
carcinoma. Pathol Oncol Res 2020;26:2489-97. DOI PubMed
